November 30, 2016 09:59 AM ESTUpdated 10:10 AM
News Briefing

Hep­tares bags GPCR tech in $12M G7 buy­out; Pfiz­er re­ports PhI­II suc­cess for Her­ceptin biosim

Shehla Shakoor

Managing Director

Lon­don-based Hep­tares has struck a deal to buy Switzer­land’s G7 Ther­a­peu­tics for about $12 mil­lion. Hep­tares was lured to the deal by G7’s ex­per­tise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times